Lexeo Therapeutics, Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. Financial statements are unaudited; amounts below are in U.S. dollars, converted from thousands unless stated otherwise.
Business context
Lexeo is a clinical-stage genetic-medicine company developing AAV gene therapies for cardiac and central nervous system diseases. Its lead candidates LX2006 (Friedreich’s ataxia cardiomyopathy) and LX1001 (APOE4-associated Alzheimer’s disease) were in Phase 1/2 trials; LX2020 (PKP2-associated arrhythmogenic cardiomyopathy) received FDA IND clearance in July 2023. The company reported early biomarker observations for LX2006 and LX1001, not evidence of established clinical benefit. Lexeo had no product sales.
Financial results and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue, all grant revenue | $0 | $0.531m | $0 | $0.654m |
| Research and development | $17.246m | $15.362m | $44.920m | $37.775m |
| General and administrative | $3.027m | $2.651m | $8.619m | $8.191m |
| Operating loss | $20.273m | $17.482m | $53.539m | $45.312m |
| Net loss | $20.108m | $17.055m | $52.207m | $44.700m |
| Net loss per share, basic and diluted | $12.36 | $10.38 | $32.24 | $27.50 |
| Cash used in operating activities | Not separately presented | Not separately presented | $45.515m | $37.934m |
At September 30, 2023, cash and cash equivalents were $35.449m, restricted cash was $3.252m, and working capital was approximately $15.839m. Total liabilities were $32.499m, including $4.147m for the SAFE note, $10.191m of operating lease liabilities and $1.870m of finance lease liabilities. Accumulated deficit was $167.653m. No operating margin is meaningful given zero revenue and ongoing development-stage losses.
Changes versus prior comparable periods
- Q3 net loss increased $3.053m year over year; nine-month net loss increased $7.507m. R&D spending rose $1.884m in Q3 and $7.145m for the nine-month period, driven mainly by clinical-trial activity, manufacturing-process work, and higher employee costs.
- Grant revenue ceased after the underlying grants wound down in 2022.
- Nine-month operating cash use increased $7.581m to $45.515m. Cash and cash equivalents fell $41.886m from December 31, 2022 to $35.449m at September 30, 2023.
- Higher interest income partly offset operating losses: $1.765m for the first nine months of 2023 versus $0.649m in 2022. A $0.272m SAFE-note fair-value loss was recorded in 2023.
Outlook, risks and unusual items
- After quarter-end, Lexeo completed its IPO on November 7, 2023 and the underwriters partially exercised their option on November 22. Net proceeds were approximately $100.049m. Management estimated cash, including the IPO proceeds, would fund planned operations and capital expenditures into Q4 2025; this is an estimate based on assumptions and is subject to change.
- The $4.0m Sarepta SAFE note, plus accrued interest, converted into 411,815 common shares when the IPO registration statement became effective. All outstanding Series A and Series B preferred stock converted into common stock at the IPO closing. A 10.594230-for-1 reverse stock split took effect October 13, 2023; share and per-share figures in the filing reflect the split.
- Management expects substantial continuing losses and higher R&D and public-company costs. Lexeo expects to need substantial additional funding over time; product revenue depends on successful development, regulatory approval and commercialization. No specific clinical milestone timetable or earnings guidance is provided in the filing.
- Rocket Pharmaceuticals sued Lexeo and two individuals on October 12, 2023, alleging trade-secret misappropriation and seeking unspecified damages and an injunction affecting cardiac gene-therapy work. Lexeo filed a motion to dismiss on December 7; it says it cannot estimate a possible loss and does not currently expect a material adverse effect on development timelines.
- Key risks include clinical and regulatory uncertainty, patient enrollment, gene-therapy safety and manufacturing challenges, reliance on third-party manufacturers and research partners, intellectual-property exposure, and access to future capital. The filing also describes serious adverse events reported in the separate LX1004 trial; these do not establish outcomes for the lead candidates.
- Following receipt of IPO proceeds, management stated there was no substantial doubt about the company’s ability to continue as a going concern for the year following issuance. Disclosure controls were assessed as effective at September 30, 2023.
Important facts for investors to verify
- Actual cash burn and whether the post-IPO runway estimate into Q4 2025 remains supportable as clinical, manufacturing and public-company costs evolve.
- Updated enrollment, safety, biomarker and efficacy data from LX2006 and LX1001, and development progress for LX2020; distinguish preliminary observations from confirmed trial results.
- The status and potential operational, financial or intellectual-property consequences of the Rocket litigation.
- Future financing needs, dilution and outstanding or planned equity awards, including the effect of the post-IPO equity plans.
- Milestone, royalty and termination obligations under license, research and manufacturing agreements, and any changes to those commitments.